TCR-T-cell trials for AML have capitalized on high-affinity HLA-A*02:01-restricted TCRs directed against WT1 (NCT01640301 and NCT02770820) [55,56] and PRAME (NCT02743611) [57] (Figure 2). The gene discussed is WT1; the disease is acute myeloid leukemia.